Werewolf Therapeutics Inc (HOWL) Actualités

Form 8-K - Current report

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug...

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity...

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...